Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DKK1 | O94907 | 3/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534498 | 1.00 | DKK1 (0.61) | DKK1PIK3CAGSK3BDYRK1ANPC1 | |
| SCHEMBL4532392 | 1.00 | DKK1 (0.61) | DKK1PIK3CAGSK3BDYRK1ANPC1 | |
| SCHEMBL3691599 | 1.00 | DKK1 (0.61) | DKK1PIK3CAGSK3BDYRK1ANPC1 | |
| SCHEMBL3648064 | 0.96 | DKK1 (0.64) | DKK1PIK3CAGSK3BDYRK1ANPC1 | |
| SCHEMBL4532479 | 0.96 | DKK1 (0.64) | DKK1PIK3CAGSK3BDYRK1ANPC1 | |
| SCHEMBL3648071 | 0.96 | DKK1 (0.64) | DKK1PIK3CAGSK3BDYRK1ANPC1 | |
| SCHEMBL4526871 | 0.94 | DKK1 (0.59) | DKK1PIK3CAGSK3BNPC1RAB9A | |
| SCHEMBL4536534 | 0.94 | DKK1 (0.59) | DKK1PIK3CAGSK3BNPC1RAB9A | |
| SCHEMBL3642659 | 0.94 | DKK1 (0.59) | DKK1PIK3CAGSK3BNPC1RAB9A | |
| SCHEMBL4535159 | 0.94 | DKK1 (0.59) | DKK1PIK3CAGSK3BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | claimed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | DKK1 9/4885PIK3CA 2494/4885GSK3B 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.